We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Moves -0.55%: What You Should Know
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed at $175.26 in the latest trading session, marking a -0.55% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.15%. Meanwhile, the Dow lost 0.52%, and the Nasdaq, a tech-heavy index, lost 0.34%.
Prior to today's trading, shares of the biotechnology company had gained 38.63% over the past month. This has outpaced the Medical sector's gain of 0.72% and the S&P 500's loss of 5.08% in that time.
Investors will be hoping for strength from Moderna as it approaches its next earnings release. On that day, Moderna is projected to report earnings of $4.73 per share, which would represent a year-over-year decline of 26.78%. Meanwhile, our latest consensus estimate is calling for revenue of $4.08 billion, down 6.23% from the prior-year quarter.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $27.27 per share and revenue of $22.39 billion. These results would represent year-over-year changes of -3.61% and +21.21%, respectively.
It is also important to note the recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% higher. Moderna currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Moderna has a Forward P/E ratio of 6.46 right now. For comparison, its industry has an average Forward P/E of 22.88, which means Moderna is trading at a discount to the group.
Also, we should mention that MRNA has a PEG ratio of 0.99. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.2 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Stock Moves -0.55%: What You Should Know
Moderna (MRNA - Free Report) closed at $175.26 in the latest trading session, marking a -0.55% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.15%. Meanwhile, the Dow lost 0.52%, and the Nasdaq, a tech-heavy index, lost 0.34%.
Prior to today's trading, shares of the biotechnology company had gained 38.63% over the past month. This has outpaced the Medical sector's gain of 0.72% and the S&P 500's loss of 5.08% in that time.
Investors will be hoping for strength from Moderna as it approaches its next earnings release. On that day, Moderna is projected to report earnings of $4.73 per share, which would represent a year-over-year decline of 26.78%. Meanwhile, our latest consensus estimate is calling for revenue of $4.08 billion, down 6.23% from the prior-year quarter.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $27.27 per share and revenue of $22.39 billion. These results would represent year-over-year changes of -3.61% and +21.21%, respectively.
It is also important to note the recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% higher. Moderna currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Moderna has a Forward P/E ratio of 6.46 right now. For comparison, its industry has an average Forward P/E of 22.88, which means Moderna is trading at a discount to the group.
Also, we should mention that MRNA has a PEG ratio of 0.99. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.2 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.